Preventive effect of Malva on urinary toxicity after radiation therapy in prostate cancer patients
A multi-centric, double-blind, randomized clinical trial
Keywords:
Malva, dysuria, radiation therapy, prostate cancerAbstract
Background: For patients receiving external beam radiation therapy (EBRT) after radical prostatectomy as adjuvant treatment or patients receiving EBRT as definitive treatment, partial irradiation of the urinary bladder is common. Many of such patients experience some degree of radiation-induced cystitis during or after EBRT. There is currently no efficient treatment for preventing radiation cystitis.
Objective: The aim of this study was to evaluate the effectiveness of one of the safe mucilaginous herbs (Malva) in preventing radiation-induced dysuria in patients who are undergoing EBRT for prostate cancer.
Methods: From April 2013 to August 2014, 68 patients were randomized into two groups using four block randomization, 34 to the drug (Malva) group and 34 to the placebo group. Of the 68 patients who began the study, 60 completed it. They were instructed to use the medication, i.e., Malva or the placebo, three times a day for six weeks. They were followed by a physician every two weeks for eight weeks, and urinary function was assessed in each visit by asking questions based on the Visual Prostate Symptom Score (VPSS) and a dysuria severity score. The changes in the VPSS and dysuria severity score between baseline and each follow-up visit were compared between the two groups in the study using repeated measures analysis of variance (ANOVA) and t-tests.
Results: The median age of the 68 patients was 66. Twenty-one of 27 patients in the control group (77.7%) suffered from dysuria, while dysuria was detected in 23 of 33 patients (69.6%) who received Malva (odds ratio=2.70 for dysuria). After two weeks, four weeks, and six weeks of treatment with Malva, dysuria due to EBRT was milder in the treatment group than in the control group, and the differences were statistically significant (p = 0.005, p = 0.004, p = 0.001, respectively).
Conclusion: To the best of our knowledge, our study is the first study to assess the protective effect of a mucilaginous herb (Malva) against urinary toxicity induced by EBRT. The positive results of this study warrant further studies in this field.
Clinical Trial Registration: The study was registered in the Iranian Clinical Trial Registry Center (IRCT2012100711026N1).
Funding: This study was supported by a grant from Tehran University of Medical Sciences
References
Loeb S, Nadler RB. Management of the complications of external beam radiotherapy and brachytherapy.
Current Prostate Reports 2006; 4(1):14-22. Doi: 10.1007/s11918-006-0017-9
Dass R, Price PW, Goosey R, Spencer M, Prütz C, Ahlgren G, et al. Estimating Prevalence of Prostate
Cancer Clinical States Using a Dynamic Patient Progression Model. Value in Health 2013; 16(7):A397- A97. Doi: 10.1016/j.jval.2013.08.428
Rosewall T, Potvin M, Bayley A, Catton C, Currie G, Wheat J, et al. The Effects of External Beam
Radiotherapy on the Normal Urinary Bladder-A Histopathological Review. J Med Imag Radiat Sci2011;
(4):189-97. Doi: 10.1016/j.jmir.2011.03.002
Dunlap C, Enos E, Thom D, Zwickey H. An Integrative Approach to Interstitial Cystitis. Explore: Explore
(NY). 2013; 9(1):48-52. Doi: 10.1016/j.explore.2012.10.004. PMID: 23294821
Razavi SM, Zarrini G, Molavi G, Ghasemi G. Bioactivity of Malva sylvestris L., a medicinal plant from
Iran. Iran J Basic Med Sci. 2011; 14(6):574. PMID: 23493458, PMCID: PMC3586856
Gruenwald J, Brendler T, Jaenicke C. PDR for herbal medicines: Thomson PDR, 2004.
Aghili Khorasani shirazi MH, 1771. Makhzan-al-Advia Edited by Rahimi R, Shams Ardekani MR,
Farjadmand F. (in persian). Tehran: Tehran University of Medical Sciences, 2009. Available from:
http://aqlibrary.org/UserFiles/File/makhzan.pdf:71.
Gasparetto JC, Martins CAF, Hayashi SS, Otuky MF, Pontarolo R. Ethnobotanical and scientific aspects of
Malva sylvestris L.: a millennial herbal medicine. J Pharm Pharmacol. 2012; 64(2):172-89. Doi:
1111/j.2042-7158.2011.01383.x. PMID: 22221093
Thapa D, Ghosh R. Antioxidants for prostate cancer chemoprevention: Challenges and opportunities.
Biochem Pharmacol. 2012; 83(10):1319-30. Doi: 10.1016/j.bcp.2011.12.027. PMID: 22248733
Ravishankar D, Rajora AK, Greco F, Osborn HMI. Flavonoids as prospective compounds for anti-cancer
therapy. Int J Biochem Cell Biol. 2013; 45(12):2821-31. Doi: 10.1016/j.biocel.2013.10.004. PMID:
Jaladat AM, Atarzadeh F, Rezaiezadeh H, Amin G. Avicenna's dietary and herbal recipe for urethral
syndrome. Infect Dis Clin Pract. 2015;23(3):168. Doi: 10.1097/ipc.0000000000000244
Jaladat AM, Atarzadeh F, Rezaiezadeh H, Mofid B, Mosalaie A, Farhan F, et al. Botanicals: An alternative
remedy to radiotherapy-induced dysuria. Compl Ther Med. 2015;23(1):90-9. Doi:
1016/j.ctim.2014.11.004
Merrick GS, Butler WM, Wallner KE, Allen Z, Galbreath RW, Lief JH. Brachytherapy‐related dysuria.
BJU international 2005; 95(4):597-602. Doi: 10.1111/j.1464-410X.2005.05346.x. PMID: 15705087
Elshaikh MA, Ulchaker JC, Reddy CA, Angermeier KW, Klein EA, Chehade N, et al. Prophylactic
tamsulosin (Flomax) in patients undergoing prostate 125I brachytherapy for prostate carcinoma: final
report of a double-blind placebo-controlled randomized study. Int J Radiat Oncol Biol Phys 2005;
(1):164-9. Doi: 10.1016/j.ijrobp.2004.09.036. PMID: 15850917
Coleman CN, Kelly L, Riese Daly N, Beard C, Kaplan I, Lamb C, et al. Phase III study of ibuprofen versus
placebo for radiation-induced genitourinary side effects. Int J Radiat Oncol Biol Phys2002; 54(1):191-94.
Doi: 10.1016/S0360-3016(02)02907-3
Blaivas JG, Weiss JP, Jones M. The pathophysiology of lower urinary tract symptoms after brachytherapy
for prostate cancer. BJU international 2006; 98(6):1233-37. Doi: 10.1111/j.1464-410X.2006.06491.x.
PMID: 17125481
Barros L, Carvalho AM, Ferreira IC. Leaves, flowers, immature fruits and leafy flowered stems of Malva
sylvestris: a comparative study of the nutraceutical potential and composition.. Food Chem Toxicol. 2010;
(6):1466-72. Doi: 10.1016/j.fct.2010.03.012. PMID: 20233600
Bonetta A, Di Pierro F. Enteric-coated, highly standardized cranberry extract reduces risk of UTIs and
urinary symptoms during radiotherapy for prostate carcinoma. Cancer Manag Res. 2012;4: 281. PMID:
PMCID: PMC3437800
Campbell G, Pickles T, D'yachkova Y. A randomised trial of cranberry versus apple juice in the
management of urinary symptoms during external beam radiation therapy for prostate cancer.Clin Oncol.
; 15(6):322-28. Doi: 10.1016/S0936-6555(03)00161-4
Martinez Figueiras N, Rey Paz M, Teijeiro Alonso M. Cranberry prevention urinary toxicity. Rep Practical
Oncol Radiother. 2013; 18:S67-S67. Doi: 10.1016/j.rpor.2013.03.741
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
